Pulmonary Arterial Hypertension (PAH) is a rare and chronic disease characterized by narrowing of the blood vessels in the lung, making it more difficult for blood to adequately flow from the heart to the lungs and disrupting one’s regular blood flow. This disruption prevents the lungs from receiving enough oxygen, putting extra strain on one’s heart, and making it harder to pump blood through the lungs and deliver oxygen.
Gossamer Bio is currently conducting a Phase 2 clinical research study evaluating the safety and efficacy of Seralutinib (AKA GB002), an inhaled investigational therapy, in adults with Pulmonary Arterial Hypertension (PAH).
Every clinical research study is different. Below are more details about the TORREY Study. When considering joining a study, ask your doctor for more information about what to expect.
- TORREY Study on clinicaltrials.gov
- 2021 PHPN Symposium Presentation
- GOSS-PHAware Podcast Episode #2
- Request More Information About TORREY